Oculis strengthens executive leadership team

Swiss ophthalmology firm Oculis Holding (Nasdaq: OCS) today announced the appointment of Dr Snehal Shah, executive leader with over two decades of research and development (R&D) and regulatory experience, to the role of president of R&D.

In this new role, Dr Shah will be responsible for leading research and development strategies, and working towards achieving market authorizations by directing global regulatory activities required for future New Drug Application (NDA) submissions to the US Food and Drug Administration (FDA), and the equivalent for regulators in other territories.

Dr Shah joins Oculis from Iveric Bio where he served as chief regulatory an Product Strategy Officer and led the successful approval of Izervay (avacincaptad pegol) for geographic atrophy in the USA. He brings over 20 years of global experience in regulatory science, R&D, pharmacovigilance, and product strategy gained at leading large, medium and biotech pharmaceutical companies including Roche (ROG: SIX) / Genentech, Noven Pharmaceuticals, Kyowa Kirin and Iveric Bio. He has a proven track record of spearheading innovative programs in various therapeutic areas including in ophthalmology for both small molecules and biologics through product development lifecycle phases from conception through commercialization.